Free Access
Med Sci (Paris)
Volume 38, Number 13, Decembre 2022
Les Cahiers de Myologie
Page(s) 46 - 48
Section Cas clinique
Published online 16 January 2023
  1. Laver DR. Regulation of the RYR channel gating by Ca2+ and Mg2. Biophys Rev 2018 ; 10 : 1087–1095. [CrossRef] [PubMed] [Google Scholar]
  2. Maggi L, Bernasconi P, D’Amico A, et al. Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurol Sci 2019 ; 40 : 457–468. [Google Scholar]
  3. Shaaban S, Ramos-Platt L, Gilles FH, et al. RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia. JAMA Ophthalmol 2013 ; 131(12):1532–1540. [CrossRef] [PubMed] [Google Scholar]
  4. Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002 ; 97 : 1067–1074. [CrossRef] [PubMed] [Google Scholar]
  5. Levano S, Vukcevic M, Singer M, et al. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009 ; 30 : 590–598. [CrossRef] [PubMed] [Google Scholar]
  6. AlBakri A, Karaoui M, Alkuraya FS, et al. Congenital ptosis, scoliosis, and malignant hyperthermia susceptibility in siblings with recessive RYR1 mutations. J AAPOS 2015 ; 19 : 577–579. [CrossRef] [PubMed] [Google Scholar]
  7. Dilaver N, Mazaheri N, Maroofian R, et al. Novel homozygous missense mutation in RYR1 leads to severe congenital ptosis, ophthalmoplegia, and scoliosis in the absence of myopathy. Mol Syndromol 2017 ; 9 : 25–29. [Google Scholar]
  8. Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015 ; 10 : 93. [Google Scholar]
  9. Alkhunaizi E, Shuster S, Shannon P, et al. Homozygous/compound heterozygote RYR1 gene variants: Expanding the clinical spectrum. Am J Med Genet A 2019 ; 179 : 386–396. [CrossRef] [PubMed] [Google Scholar]
  10. Robb SA, Sewry CA, Dowling JJ, et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 2011 ; 21 : 379–386. [Google Scholar]
  11. Illingworth MA, Main M, Pitt M, et al. RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine. Neuromuscul Disord 2014 ; 24 : 707–712. [Google Scholar]
  12. Liewluck T, Shen XM, Milone M, et al. Endplate structure and parameters of neuromuscular transmission in sporadic centronuclear myopathy associated with myasthenia. Neuromuscul Disord 2011 ; 21 : 387–395. [Google Scholar]
  13. Beecroft SJ, Lombard M, Mowat D, et al. Genetics of neuromuscular fetal akinesia in the genomics era. J Med Genet 2018 ; 55 : 505–514. [Google Scholar]
  14. Colombo I, Scoto M, Manzur AY, et al. Congenital myopathies: Natural history of a large pediatric cohort. Neurology 2015 ; 84 : 28–35. [Google Scholar]
  15. Lawal TA, Todd JJ, Meilleur KG. Ryanodine Receptor 1-related myopathies: diagnostic and therapeutic approaches. Neurotherapeutics 2018 ; 15 : 885–899. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.